NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements

Chinese Medicine

Volumn 7, Issue , 2012, Pages

  Lachenmeier, Dirk W ^a   Monakhova, Yulia B ^a,b,c   Kuballa, Thomas ^a   Löbell Behrends, Sigrid ^a   Maixner, Sibylle ^a   Kohl Himmelseher, Matthias ^a   Waldner, Asja ^d   Steffen, Christian ^e  

^a Chemisches und Veterinaruntersuchungsamt CVUA Karlsruhe   (Germany)

^b BRUKER BIOSPIN GMBH   (Germany)

^c SARATOV STATE UNIVERSITY   (Russian Federation)

^d Regierungspräsidium Tübingen   (Germany)

^e NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ARTICLE; DIET SUPPLEMENTATION; DRUG DETERMINATION; ENZYME ACTIVITY; LIMIT OF DETECTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84858741690     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-7-8     Document Type: Article

References (52)

1. Wang TH, Lin TF. Monascus rice products. Adv Food Nutr Res 2007, 53:123-159.
2. DFG - Senate Commission on Food Safety Toxicological evaluation of red mould rice 2005, Bonn, Germany: Deutsche Forschungsgemeinschaft (DFG) [German Research Foundation], DFG - Senate Commission on Food Safety.
3. Henwood JM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988, 36:429-454. 10.2165/00003495-198836040-00003, 3069436.
4. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003, 2:517-526. 10.1038/nrd1112, 12815379.
5. Havel RJ. Dietary supplement or drug? The case of cholestin. Am J Clin Nutr 1999, 69:175-176.
6. . EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2011, 9:2304. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).
7. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999, 69:231-236.
8. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005, 153:679-686. 10.1530/eje.1.02012, 16260426.
9. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830-839.
10. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, Thompson PD, Rader DJ, Becker DJ. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198-204. 10.1016/j.amjcard.2009.08.672, 20102918.
11. Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, Retterstøl K. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand Cardiovasc J 2010, 44:197-200. 10.3109/14017431003624123, 20636227.
12. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006, 1:4. 10.1186/1749-8546-1-4, 1761143, 17302963.
13. Man RY, Lynn EG, Cheung F, Tsang PS, O K. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 2002, 233:153-158. 10.1023/A:1017487815091, 12083370.
14. Polsani VR, Jones PH, Ballantyne CM, Nambi V. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol 2008, 2:60-62. 10.1016/j.jacl.2007.12.005, 21291717.
15. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, Gori L, Firenzuoli F, Mugelli A, Vannacci A. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol 2008, 66:572-574. 10.1111/j.1365-2125.2008.03224.x, 2561108, 18637891.
16. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J 2003, 96:1265-1267. 10.1097/01.SMJ.0000100117.79718.DC, 14696880.
17. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002, 74:1200-1201. 10.1097/00007890-200210270-00028, 12438974.
18. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med 2006, 145:474-475.
19. Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012, 12(1):54-61. DOI: 10.1007/s11910-011-0232-9, 10.1007/s11910-011-0232-9, 21968786.
20. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med 2008, 149:516-517.
21. Hipler UC, Wigger-Alberti W, Bauer A, Elsner P. Monascus purpureus-a new fungus of allergologic relevance. Mycoses 2002, 45:58-60.
22. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997, 32:403-425. 10.2165/00003088-199732050-00005, 9160173.
23. Vaquero MP, Sánchez Muniz FJ, Jiménez Redondo S, Prats Oliván P, Higueras FJ, Bastida S. Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins. Nutr Hosp 2010, 25:193-206.
24. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995, 52:1639-1645.
25. Messer A, Raquet N, Lohr C, Schrenk D. Major furocoumarins in grapefruit juice II: Phototoxicity, photogenotoxicity, and inhibitory potency vs. cytochrome P450 3A4 activity. Food Chem Toxicol 2012, 50(3-4):756-760. DOI: 10.1016/j.fct.2011.11.023, 10.1016/j.fct.2011.11.023, 22155270.
26. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998, 46:101-110. 1873672, 9723817.
27. Huang HN, Hua YY, Bao GR, Xie LH. The quantification of monacolin K in some red yeast rice from Fujian province and the comparison of the other product. Chem Pharm Bull (Tokyo) 2006, 54:687-689.
28. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware. Arch Intern Med 2010, 170:1722-1727. 10.1001/archinternmed.2010.382, 20975018.
29. Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal 2004, 35:1101-1112. 10.1016/j.jpba.2004.04.004, 15336357.
30. Chairote E, Chairote G, Niamsup H, Lumyong S. The presence and the content of Monacolins in Red Yeast rice prepared from Thai glutinous rice. World J Microbiol Biotechnol 2008, 24:3039-3047.
31. Chairote E, Lumyong S, Chairote G. Study on cholesterol lowering compounds in red yeast rice prepared from Thai glutinous rice. As J Food Ag-Ind 2010, 3:217-228.
32. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, Zhang D, Cooper R, Chang M. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000, 48:5220-5225. 10.1021/jf000338c, 11087463.
33. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001, 7:133-139. 10.1089/107555301750164181, 11327519.
34. Song F, El-Demerdash A, Lee SJ, Smith RE. Fast screening of lovastatin in red yeast rice products by flow injection tandem mass spectrometry. J Pharm Biomed Anal 2012, 57:76-81.
35. Steffen C. Abgrenzungsproblematik. Klinische Studien mit Nahrungsergänzungsmitteln. Pharm Unserer Zeit 2011, 40:332-337. 10.1002/pauz.201100428, 21698632.
36. Holzgrabe U, Wawer I, Diehl B. NMR spectroscopy in pharmaceutical analysis 2008, Amsterdam, The Netherlands: Elsevier Science.
37. Kerpel-Fronius S, Fischer J. Optimizing the clinical pharmacologic properties of the HMG-CoA reductase inhibitors. Analogue-based Drug Discovery 2006, 137-156. Weinheim, Germany: Wiley-VCH, Fischer J, Ganellin CR.
38. Löbell-Behrends S, Maixner S, Kratz E, Kohl-Himmelseher M, Bauer-Aymanns H, Marx G, Lachenmeier DW. Surveillance of internet marketing of borderline products (anti-aging and weight-loss supplements): A pilot study. Deut Lebensm Rundsch 2008, 104:265-270.
39. Löbell-Behrends S, Böse W, Maixner S, Kratz E, Kohl-Himmelseher M, Marx G, Lachenmeier DW. Surveillance of internet marketing of food products - categorization of borderline products and concepts for effective control strategies. J Verbr Lebensm 2011, 6:385-393.
40. Monakhova YB, Schäfer H, Humpfer E, Spraul M, Kuballa T, Lachenmeier DW. Application of automated eightfold suppression of water and ethanol signals in 1H NMR to provide sensitivity for analyzing alcoholic beverages. Magn Reson Chem 2011, 49:734-739. 10.1002/mrc.2823, 22002683.
41. Schaller RB, Munk ME, Pretsch E. Spectra estimation for computer-aided structure determination. J Chem Inf Comput Sci 1996, 36:239-243.
42. DIN 32 645 Chemische Analytik: Nachweis-, Erfassungs- und Bestimmungsgrenze, Ermittlung unter Wiederholbedingungen. Begriffe, Verfahren, Auswertung 1994, Berlin, Germany: Beuth Verlag, DIN 32 645.
43. Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S, Gao G, Luo D, Minatoya M, Lushington GH. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int J Mol Med 2009, 24:633-643. 2941436, 19787197.
44. Chen LC, Lai YK, Wu SC, Lin CC, Guo JH. Production by Clonostachys compactiuscula of a lovastatin esterase that converts lovastatin to monacolin J. Enzyme Microb Technol 2006, 39:1051-1059.
45. Diehl BWK, Holzgrabe U. Analysis of Drugs. NMR Spectroscopy in Drug Development and Analysis 1999, 16-60. Weinheim, Germany: Wiley-VCH, Holzgrabe U, Wawer I, Diehl B.
46. Holzgrabe U, Diehl BW, Wawer I. NMR spectroscopy in pharmacy. J Pharm Biomed Anal 1998, 17:557-616. 10.1016/S0731-7085(97)00276-8, 9682143.
47. Ahmad A, Panda BP, Khan S, Ali M, Javed S. Downstreaming and purification of lovastatin from Monascus purpureus culture. Thai J Pharm Sci 2009, 33:39-46.
48. Lankhorst PP, Poot MM, de Lange MPA. Quantitative Determination of Lovastatin and Dihydrolovastatin by Means of 1H NMR Spectroscopy. Pharmacopeial Forum 1996, 22:2414-2422.
49. Juzlová P, Martinková L, Kren V. Secondary metabolites of the fungus Monascus: a review. J Ind Microbiol Biotechnol 1996, 16:163-170.
50. Walker JF, Tobert JA. The clinical efficacy and safety of lovastatin and MK-733-an overview. Eur Heart J 1987, 8(Suppl. E):93-96.
51. Lamson M, Phillips G, Shen J, Lukacsko P, Friedhoff L, Niecestro RM. Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos 2002, 23:143-149. 10.1002/bdd.304, 12015788.
52. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN, Nash DT, Langendorfer A. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992, 85:1293-1303.